ANNX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Current Price	$3.22
Today's Volume	698 490
Average Volume	800 004
Market Cap	170.93M
EPS	$-2.30
P/E	-1.400
ATR14	$0.230 (7.11%)

Volume Correlation

Long: 0.62 (weak)

Short: 0.92 (very strong)

Signal:(67) Expect same movement, but be aware

Correlation (AI algo v.1.1b): Overvalued: -0.65% $3.21 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Annexon, Inc. Correlation

10 Most Positive Correlations
SDG	0.909
VNQI	0.903
FHTX	0.884
CXSE	0.876
BMRN	0.871
TRUE	0.87
ASET	0.865
EMXF	0.861
ZNTL	0.859
SPRO	0.858

10 Most Negative Correlations
MDWT	-0.896
ROKU	-0.878
IBKR	-0.862
TRNS	-0.851
NVTS	-0.849
PLUS	-0.84
SIGI	-0.836
BIS	-0.829
MRCY	-0.827
PACW	-0.82

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Annexon, Inc. Correlation - Currency/Commodity

0.44
( neutral )

0.40
( neutral )

0.00
( neutral )

0.69
( moderate )

0.00
( neutral )

-0.52
( weak negative )

Annexon, Inc. Financials

Annual 2022
Revenue: $0
Gross Profit: $0 (0.00%)
EPS: $-2.53

Q1 2023
Revenue: $0
Gross Profit: $0 (0.00%)
EPS: $-0.480

Q4 2022
Revenue: $0
Gross Profit: $0 (0.00%)
EPS: $-0.630

Q3 2022
Revenue: $0
Gross Profit: $0 (0.00%)
EPS: $-0.500

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.